<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE collection SYSTEM "BioC.dtd">
<collection><source>PMC</source><date>20220802</date><key>pmc.key</key><document><id>9242884</id><infon key="license">NO-CC CODE</infon><passage><infon key="article-id_doi">10.1016/j.jcjo.2022.06.016</infon><infon key="article-id_pii">S0008-4182(22)00189-2</infon><infon key="article-id_pmc">9242884</infon><infon key="article-id_pmid">35868440</infon><infon key="license">Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</infon><infon key="name_0">surname:Ugurlu;given-names:Adem</infon><infon key="name_1">surname:Agcayazi;given-names:Sümeyye Burcu</infon><infon key="name_2">surname:Icel;given-names:Erel</infon><infon key="name_3">surname:Budakoglu;given-names:Ozlem</infon><infon key="name_4">surname:Unver;given-names:Edhem</infon><infon key="name_5">surname:Barkay;given-names:Orçun</infon><infon key="name_6">surname:Karakeçili;given-names:Faruk</infon><infon key="name_7">surname:Bayrakceken;given-names:Kemal</infon><infon key="section_type">TITLE</infon><infon key="type">front</infon><infon key="year">2022</infon><offset>0</offset><text>Assessment of the optic nerve, macular, and retinal vascular effects of COVID-19</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>81</offset><text>Objective</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>91</offset><text>To evaluate the effects of SARS-CoV-2 infection on the optic nerve, macula, and retinal vascular structures.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>200</offset><text>Methods</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>208</offset><text>This study included 129 participants recovering from COVID-19 and 130 healthy control subjects aged 18 to 55 years. The study was designed as observational and cross-sectional and was conducted between June 2020 and February 2021. The average thicknesses of the retinal nerve fibre layer (RNFL), ganglion cell complex (GCC), and macula also were measured using a spectral domain optical coherence tomography analysis. The vessel densities of the superficial and deep capillary plexuses of the macula, foveal avascular zone, and radial peripapillary capillary plexus of the optic disc were quantified by optical coherence tomography angiography.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>853</offset><text>Results</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>861</offset><text>In all quadrants, the RNFL and GCC were thinner in patients with neurologic symptoms of COVID-19 (p &lt; 0.05). None of the measurements of the Early Treatment Diabetic Retinopathy Study regions significantly differed between patients with and without COVID-19 symptoms (p &gt; 0.05). The foveal avascular zone area, perimeter, circularity index, and vessel densities (%) of the global and inner and outer circles of superficial capillary plexuses and deep capillary plexus and global and superior and inferior halves of the radial peripapillary capillary plexus measurements were found to significantly differ between the symptomatic COVID-19 group and the asymptomatic COVID-19 and control groups (p &lt; 0.05).</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>1566</offset><text>Conclusion</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>1577</offset><text>RNFL and GCC thickness evaluation with optical coherence tomography and vessel density evaluation with optical coherence tomography angiography can be considered remarkable diagnostic methods for retinal neurovascular abnormalities and a biomarker for microvascular abnormalities after infection with SARS-CoV-2.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>1890</offset><text>The pathogen of COVID-19, known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is an RNA virus that primarily affects the upper and lower respiratory tracts. The novel type of coronavirus disease (COVID-19), first detected in Wuhan, China, in December 2019, was declared a pandemic by the World Health Organization in March 2020. As is known, COVID-19 is a disease that has effects on the central nervous and cardiovascular systems as well as the respiratory system. In individuals who have had COVID-19 disease, retinal tissue also may vary depending on the effects on the central nervous or vascular system.   </text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>2521</offset><text>SARS-CoV-2 binds to angiotensin-converting enzyme 2 (ACE2) receptors on cell surfaces, and the virus–receptor interaction is thought to reduce ACE2 action and increase levels of angiotensin II, a strong capillary vasoconstrictor, which propagates microvascular damage. </text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>2793</offset><text>This study aimed to investigate the possible effects of COVID-19 disease on the optic nerve, macula, and retinal vascular structure.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_1</infon><offset>2926</offset><text>Methods</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>2934</offset><text>This study was designed as observational and cross-sectional study and was conducted in the Ophthalmology, Pulmonology and Infectious Diseases Departments of the Erzincan Binali Yildirim University Faculty of Medicine between June 2020 and February 2021. Ethical approval was obtained from the local ethics committee (Approval Number E-21142744-804.99-70916), and detailed informed consent was taken from all participants. The principles of the Declaration of Helsinki were adhered to throughout this study.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>3442</offset><text>Study design and participants</text></passage><passage><infon key="file">tbl0001.xml</infon><infon key="id">tbl0001</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>3472</offset><text>Systemic examination results of the COVID-19 group at presentation</text></passage><passage><infon key="file">tbl0001.xml</infon><infon key="id">tbl0001</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;th valign=&quot;top&quot;&gt;Symptom&lt;/th&gt;&lt;th valign=&quot;top&quot;&gt;n (%)&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Respiratory symptoms&lt;/td&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Cough&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;21/129 (16.3%)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Sore throat&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;14/129 (10.9%)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Rhinorrhea, sneezing&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;7/129 (5.4%)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Pneumonia&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;20/129 (15.5%)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Dyspnea&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;12/129 (9.3%)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Hypoxemia&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;11/129 (8.5%)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Neurologic symptoms&lt;/td&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Hyposmia/anosmia&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;7/129 (5.4%)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Hypogeusia/ageusia&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;7/129 (5.4%)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Visual disturbance&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;4/129 (3.1%)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Fatigue, somnolence&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;11/129 (8.5%)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Headache&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;18/129 (14%)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Dizziness&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;9/129 (7%)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Myalgia&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;12/129 (9.3%)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Tinnitus&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;6/129 (4.7%)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Diplopia&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;3/129 (2.3%)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Cardiovascular symptoms&lt;/td&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Chest pain&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;10/129 (7.8%)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Arrhythmia&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;7/129 (5.4%)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Sinus tachycardia&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;5/129 (3.9%)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Blood coagulation&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;13/129 (10.1%)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Arterial or venous thromboembolism&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;10/129 (7.8%)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Pulmonary embolism&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;7/129 (5.4%)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Gastrointestinal symptoms&lt;/td&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Nausea and vomiting&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;11/129 (8.5%)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Diarrhea&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;9/129 (7%)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Loss of appetite&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;10/129 (7.8%)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Abdominal pain&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;8/129 (6.2%)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Bloating&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;7/129 (5.4%)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Heartburn&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;5/129 (3.9%)&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>3539</offset><text>Table 1	 	</text></passage><passage><infon key="file">tbl0001.xml</infon><infon key="id">tbl0001</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;th valign=&quot;top&quot;&gt;Symptom&lt;/th&gt;&lt;th valign=&quot;top&quot;&gt;n (%)&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Respiratory symptoms&lt;/td&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Cough&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;21/129 (16.3%)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Sore throat&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;14/129 (10.9%)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Rhinorrhea, sneezing&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;7/129 (5.4%)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Pneumonia&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;20/129 (15.5%)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Dyspnea&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;12/129 (9.3%)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Hypoxemia&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;11/129 (8.5%)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Neurologic symptoms&lt;/td&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Hyposmia/anosmia&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;7/129 (5.4%)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Hypogeusia/ageusia&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;7/129 (5.4%)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Visual disturbance&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;4/129 (3.1%)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Fatigue, somnolence&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;11/129 (8.5%)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Headache&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;18/129 (14%)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Dizziness&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;9/129 (7%)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Myalgia&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;12/129 (9.3%)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Tinnitus&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;6/129 (4.7%)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Diplopia&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;3/129 (2.3%)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Cardiovascular symptoms&lt;/td&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Chest pain&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;10/129 (7.8%)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Arrhythmia&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;7/129 (5.4%)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Sinus tachycardia&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;5/129 (3.9%)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Blood coagulation&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;13/129 (10.1%)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Arterial or venous thromboembolism&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;10/129 (7.8%)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Pulmonary embolism&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;7/129 (5.4%)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Gastrointestinal symptoms&lt;/td&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Nausea and vomiting&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;11/129 (8.5%)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Diarrhea&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;9/129 (7%)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Loss of appetite&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;10/129 (7.8%)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Abdominal pain&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;8/129 (6.2%)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Bloating&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;7/129 (5.4%)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Heartburn&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;5/129 (3.9%)&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>3550</offset><text>Symptom	n (%)	 	Respiratory symptoms		 	Cough	21/129 (16.3%)	 	Sore throat	14/129 (10.9%)	 	Rhinorrhea, sneezing	7/129 (5.4%)	 	Pneumonia	20/129 (15.5%)	 	Dyspnea	12/129 (9.3%)	 	Hypoxemia	11/129 (8.5%)	 	Neurologic symptoms		 	Hyposmia/anosmia	7/129 (5.4%)	 	Hypogeusia/ageusia	7/129 (5.4%)	 	Visual disturbance	4/129 (3.1%)	 	Fatigue, somnolence	11/129 (8.5%)	 	Headache	18/129 (14%)	 	Dizziness	9/129 (7%)	 	Myalgia	12/129 (9.3%)	 	Tinnitus	6/129 (4.7%)	 	Diplopia	3/129 (2.3%)	 	Cardiovascular symptoms		 	Chest pain	10/129 (7.8%)	 	Arrhythmia	7/129 (5.4%)	 	Sinus tachycardia	5/129 (3.9%)	 	Blood coagulation	13/129 (10.1%)	 	Arterial or venous thromboembolism	10/129 (7.8%)	 	Pulmonary embolism	7/129 (5.4%)	 	Gastrointestinal symptoms		 	Nausea and vomiting	11/129 (8.5%)	 	Diarrhea	9/129 (7%)	 	Loss of appetite	10/129 (7.8%)	 	Abdominal pain	8/129 (6.2%)	 	Bloating	7/129 (5.4%)	 	Heartburn	5/129 (3.9%)	 	</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>4466</offset><text>Patients diagnosed with COVID-19 confirmed by laboratory-confirmed SARS-CoV-2 infection based on a positive polymerase chain reaction (PCR) test by an infectious diseases specialist and (or) a pulmonologist were included in the study. All patients in the COVID-19 group included in the study were called for ophthalmologic examinations after PCR negativity was observed. All the patients were included in this study at the earliest 29 and the latest 45 days after COVID-19 PCR positivity was detected. The participants with COVID-19 were divided into 3 groups according to their admission symptoms as neurologic, nonneurologic (e.g., respiratory, cardiovascular, and gastrointestinal), and asymptomatic or paucisymptomatic. Asymptomatic patients included in the study consisted of patients who had a history of contact with patients with COVID-19 and who wanted to have a PCR test without any complaints. Systemic examination results of the COVID-19 group at presentation are shown in Table 1 . Patients were also divided into symptomatic and asymptomatic in the COVID-19 group.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>5545</offset><text>The demographic and clinical data of 184 patients who recovered completely from COVID-19 were evaluated. Fifty-five participants were excluded from the study based on the criteria given in the following section. The final sample included 129 participants recovering from COVID-19 and 130 control subjects aged between 18 and 55 years with a visual acuity of ≥20/20, axial length of 22–24.5 mm, refractive error spherical equivalent of ±3 D or less, and intraocular pressure (IOP) of 21 mm Hg or less. All the control subjects were evaluated between 2018 and 2019 for the normative data assessment of vessel density and foveal avascular zone metrics using AngioScan software study in our clinic. Only the right eyes of all the participants were included.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>6304</offset><text>Exclusion criteria</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>6323</offset><text>Individuals who had systemic diseases, such as hypertension, diabetes, and cardiovascular and neurologic problems; those with ocular disorders such as glaucoma, cataract, retinal vascular, and (or) macular diseases; those with previous ocular surgery and/or trauma; and those who had 2 or more of the neurologic, cardiovascular, respiratory, and gastrointestinal admission symptoms, were excluded from the study.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>6736</offset><text>Ophthalmological examinations</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>6766</offset><text>A detailed ophthalmologicalal examination was performed, including autorefractometry (Tonoref III, Nidek Co Ltd, Bunkyo City, Japan), best-corrected visual acuity analysis, slit-lamp biomicroscopy, and IOP measurement with a Goldmann applanation tonometer. The axial length was measured with the ALSCAN (Nidek Co. Ltd) device in all patients.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>7109</offset><text>Pulmonological examinations</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>7137</offset><text>The patients’ complaints, such as cough, fever, weakness, fatigue, joint pain, shortness of breath, headache, sore throat, chest pain, back pain, decreased sense of smell and taste, and diarrhea, were questioned. Respiratory system examinations (i.e., inspection, percussion, palpation, and auscultation) were performed. Laboratory examinations that could suggest macrophage activation syndrome (e.g., hemogram, routine biochemistry, acute-phase reactants, and parameters such as ferritin, d-dimer, and fibrinogen) also were examined. In addition, the patients were radiologically evaluated in terms of COVID-19 using thoracic computed tomography (16-slice computed tomography canner; Sensation 16, Siemens Medical Systems, Erlangen, Germany), posteroanterior chest radiography, and PCR.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>7927</offset><text>Infectious disease examinations</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>7959</offset><text>Patients were evaluated in terms of oral cavity mucosal involvement, cervical lymphadenopathies, thyroid sensitivity, cardiac murmurs, abdominal sensitivity, and rashes. The complete blood count, serum C-reactive protein, procalcitonin, d-dimer, and ferritin levels were measured.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>8240</offset><text>COVID-19 treatment algorithm</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>8269</offset><text>The treatment algorithm recommended by the Ministry of Health of the Republic of Turkey was followed for the symptomatic patients diagnosed with COVID-19 based on PCR positivity. This algorithm includes favipiravir 1600 mg/day for 3 days, 600 mg/day for 5 days for maintenance, and enoxaparin 4000 mIU/mL per day (body mass index &lt;30 kg/m2) or 8000 mIU/mL per day (body mass index &gt;30 kg/m2) for 1 week. In severe cases, the maintenance dose of favipiravir was extended to 10 days and enoxaparin to 14 days.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>8777</offset><text>Optical coherence tomography and optical coherence tomography angiographyscan procedures</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>8866</offset><text>The macular and peripapillary thicknesses were measured using a spectral-domain Optical coherence tomography (SD-OCT) device (Nidek Co Ltd). The Nidek RS-3000 Advance OCT system was used to evaluate the SD-OCT images. The average thicknesses of the retinal nerve fibre layer (RNFL), ganglion cell complex (GCC), and macula also were determined with SD-OCT analysis. The RNFL measurements for the mean, superior, inferior, temporal, and nasal quadrants were performed from a 6 × 6 mm2 ring centred on the optic nerve head and recorded. From the 6 × 6 mm2 macular map, macular thicknesses were measured from the 9 zones described by the Early Treatment Diabetic Retinopathy Study (ETDRS), and the superior and inferior GCC thicknesses also were recorded. The subfoveal choroidal thickness was measured at 3 points (central foveal, 500 µm nasal, and temporal of the central foveal), and the average of these 3 values was determined as the final thickness.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>9830</offset><text>The vessel densities of the superficial (SCP) and deep capillary plexuse (DCP) of the macula, foveal avascular zone (FAZ), and the vessel density of the radial peripapillary capillary plexus (RPCP) for the optic disc were quantified using OCT- angiographyscan (OCT-A; RS-3000 Advance, Nidek Co Ltd). Updated AngioScan software (version 1.8.0; Navis, Gamagori, Japan). of Nidek's RS-3000 Advance system was used to evaluate the OCT-A images. This software automatically calculates the macular and peripapillary vessel densities as well as the FAZ. The fovea was focused on using an OCT-A prototype internal fixation lamp, and 3 × 3 mm2 macular cubes, each consisting of 256 B-scans, were generated. For the retinal peripapillary capillary plexus, the scans included a 2.4 × 4 mm2 disc map centred on the optic nerve head. The updated software of Nidek's RS-3000 Advance device allows removing the projection artifacts of OCT-A scans through the ALL Layers projection artifact removal feature. From the macular OCT-A scans, the FAZ circularity index (values closer to 1 indicate higher circularity), area and perimeter, and the vessel densities of the global whole-image SCP and DCP, outer and inner superficial capillary plexuses, deep capillary plexus rings, and 9 ETDRS regions were evaluated.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>11135</offset><text>SD-OCT and OCT-A measurements were performed by an experienced ophthalmologist after pupil dilation with a 1% tropicamide eye drop (Tropamid, Bilim Ilac Ltd, Istanbul, Turkey). In cases where the signal strength index quality was &lt;7/10, scanning was repeated. FAZ (with a 3 × 3 mm2 OCT-A measurement field) and the vessel densities of the SCP and DCP were measured. Automated segmentation was performed to determine the en face slab for the superficial and deep retinal layers extending from the internal limiting membrane to 13 μm below the inner nuclear layer and from 8 μm below the inner nuclear layer to 13 μm below the outer nuclear layer, respectively. Vessel densities were calculated as the percentage area filled by flowing blood vessels in the selected region. The vessel density of RPCP for the superior/inferior (S/I) and temporal superior nasal inferior temporal (TSNIT) sectors was obtained from the OCT-A scans of the peripapillary area. In the study, all the numerical values of the vessel densities were obtained automatically by the OCT-A device. The segmentation algorithm also was selected automatically by the device.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>12283</offset><text>Statistical analysis</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>12304</offset><text>The Statistical Package for the Social Sciences (SPSS Inc., Chicago, Ill.) version 23.0 was used for statistical analysis of the data. G-Power analysis was not performed because the study was exploratory. Data on continuous variables were expressed as mean ± SD and those of categorical variables as frequency and percentages. Whether the data were normally distributed was determined with the Shapiro–Wilk test. In the analysis comparing the groups, the analysis of variance test with the Bonferroni correction was performed for continuous variables with a normal distribution and the Mann–Whitney U test for the comparison of quantitative data without a normal distribution. The Pearson and Spearman correlation tests were used to evaluate the correlations between variables. After checking collinearity diagnostics, a multivariate regression analysis corrected for age, sex, image quality, intraocular pressure, and axial length was used to determine the associations between the RNFL and GCC thicknesses as dependent variables and the vessel densities of the SCP, DCP, and RPCP as independent variables in the COVID-19 group. Statistical results were stated at the 95% CI and given with the regression coefficient (β) in the regression analysis. Statistical significance was evaluated at the level of p &lt; 0.05.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_1</infon><offset>13625</offset><text>Results</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>13633</offset><text>Demographic and clinical data</text></passage><passage><infon key="file">tbl0002.xml</infon><infon key="id">tbl0002</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>13663</offset><text>Demographic, ophthalmologic, and clinical data on the study participants</text></passage><passage><infon key="file">tbl0002.xml</infon><infon key="id">tbl0002</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;th valign=&quot;top&quot;&gt;Factor&lt;/th&gt;&lt;th valign=&quot;top&quot;&gt;COVID-19&lt;/th&gt;&lt;th valign=&quot;top&quot;&gt;Control&lt;/th&gt;&lt;th valign=&quot;top&quot;&gt;&lt;italic&gt;p&lt;/italic&gt; Value&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Number of participants&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;129&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;130&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;—&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Sex (F/M)&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;64/60&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;68/62&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;&amp;gt;0.05&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Mean age ± SD (y)&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;42.3 ± 13.8&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;44.9 ± 12.4&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;&amp;gt;0.05&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Mean BCVA ± SD (logMAR)&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;–0.07 ± 0.06&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;–0.06 ± 0.05&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;&amp;gt;0.05&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Average IOP ± SD (mm Hg)&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;15.2 ± 4.5&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;15.1 ± 4.3&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;&amp;gt;0.05&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Mean AL ± SD (mm)&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;23.05 ± 1.1&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;23.12 ± 0.92&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;&amp;gt;0.05&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Asymptomatic/paucisymptomatic&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;32/129&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;—&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;—&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Neurologic symptoms&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;38/129&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;—&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;—&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Cardiovascular symptoms&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;17/129&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;—&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;—&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Respiratory symptoms&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;29/129&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;—&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;—&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Hospitalization&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;58/129&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;—&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;—&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Oxygen therapy&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;42/129&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;—&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;—&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Intensive care requirement&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;8/129&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;—&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;—&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>13736</offset><text>Table 2	 	</text></passage><passage><infon key="file">tbl0002.xml</infon><infon key="id">tbl0002</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;th valign=&quot;top&quot;&gt;Factor&lt;/th&gt;&lt;th valign=&quot;top&quot;&gt;COVID-19&lt;/th&gt;&lt;th valign=&quot;top&quot;&gt;Control&lt;/th&gt;&lt;th valign=&quot;top&quot;&gt;&lt;italic&gt;p&lt;/italic&gt; Value&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Number of participants&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;129&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;130&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;—&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Sex (F/M)&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;64/60&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;68/62&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;&amp;gt;0.05&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Mean age ± SD (y)&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;42.3 ± 13.8&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;44.9 ± 12.4&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;&amp;gt;0.05&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Mean BCVA ± SD (logMAR)&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;–0.07 ± 0.06&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;–0.06 ± 0.05&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;&amp;gt;0.05&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Average IOP ± SD (mm Hg)&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;15.2 ± 4.5&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;15.1 ± 4.3&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;&amp;gt;0.05&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Mean AL ± SD (mm)&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;23.05 ± 1.1&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;23.12 ± 0.92&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;&amp;gt;0.05&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Asymptomatic/paucisymptomatic&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;32/129&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;—&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;—&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Neurologic symptoms&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;38/129&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;—&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;—&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Cardiovascular symptoms&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;17/129&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;—&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;—&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Respiratory symptoms&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;29/129&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;—&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;—&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Hospitalization&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;58/129&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;—&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;—&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Oxygen therapy&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;42/129&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;—&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;—&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Intensive care requirement&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;8/129&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;—&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;—&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>13747</offset><text>Factor	COVID-19	Control	p Value	 	Number of participants	129	130	—	 	Sex (F/M)	64/60	68/62	&gt;0.05	 	Mean age ± SD (y)	42.3 ± 13.8	44.9 ± 12.4	&gt;0.05	 	Mean BCVA ± SD (logMAR)	–0.07 ± 0.06	–0.06 ± 0.05	&gt;0.05	 	Average IOP ± SD (mm Hg)	15.2 ± 4.5	15.1 ± 4.3	&gt;0.05	 	Mean AL ± SD (mm)	23.05 ± 1.1	23.12 ± 0.92	&gt;0.05	 	Asymptomatic/paucisymptomatic	32/129	—	—	 	Neurologic symptoms	38/129	—	—	 	Cardiovascular symptoms	17/129	—	—	 	Respiratory symptoms	29/129	—	—	 	Hospitalization	58/129	—	—	 	Oxygen therapy	42/129	—	—	 	Intensive care requirement	8/129	—	—	 	</text></passage><passage><infon key="file">tbl0002.xml</infon><infon key="id">tbl0002</infon><infon key="section_type">TABLE</infon><infon key="type">table_footnote</infon><offset>14350</offset><text>F = female; M = male; BCVA = best-corrected visual acuity; IOP = intraocular pressure;</text></passage><passage><infon key="file">tbl0002.xml</infon><infon key="id">tbl0002</infon><infon key="section_type">TABLE</infon><infon key="type">table_footnote</infon><offset>14453</offset><text>AL = axial length</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>14475</offset><text>The demographic and clinical data of the participants are presented in Table 2 . A total of 129 participants recovering from COVID-19 and 130 control subjects were enrolled in the study. Only the right eyes of all the participants were included in the evaluations. All the participants were white. Sixty-seven of the individuals in the COVID-19 group and 68 in the control group were female (p &gt; 0.05). The mean age was 42.3 ± 13.8 years (range, 18–55 years) in the COVID-19 group and 44.9 ± 12.4 years (range, 18–55 years) in the control group. There were no differences between the 2 groups in terms of mean age, best-corrected visual acuity, IOP, and axial length (p &gt; 0.05). And in addition, there were no significant differences between the subgroups in patients with COVID-19 in terms of age and sex (p &gt; 0.05). Severe cases were hospitalized. Hospitalization rates were 18 of 38 (47.4%) in patients with neurologic symptoms and 40 of 59 (67.8%) in patients with nonneurologic symptoms. In patients with neurologic symptoms, 8 (21%) were taking oxygen therapy, whereas in patients with nonneurological symptoms, 34 (57.6%) were taking oxygen therapy. Only the patients who needed intensive care were intubated. All patients needing intensive care were admitted with nonneurological symptoms.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>15779</offset><text>Systemic examination and laboratory results</text></passage><passage><infon key="file">tbl0003.xml</infon><infon key="id">tbl0003</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>15823</offset><text>Laboratory findings of participants with COVID-19 at first visit</text></passage><passage><infon key="file">tbl0003.xml</infon><infon key="id">tbl0003</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;th valign=&quot;top&quot;&gt;Laboratory test&lt;/th&gt;&lt;th valign=&quot;top&quot;&gt;Asymptomatic&lt;/th&gt;&lt;th valign=&quot;top&quot;&gt;Neurologic&lt;/th&gt;&lt;th valign=&quot;top&quot;&gt;Nonneurologic&lt;/th&gt;&lt;th valign=&quot;top&quot;&gt;&lt;italic&gt;p&lt;/italic&gt; Value&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Neutrophils (× 10&lt;sup&gt;3&lt;/sup&gt;/μL)&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;6.22 ± 2.15&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;8.19 ± 3.74&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;10.36 ± 4.98&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;&amp;lt;0.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Lymphocytes (× 10&lt;sup&gt;3&lt;/sup&gt;/μL)&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;2.17 ± 0.92&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;1.06 ± 2.56&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;0.68 ± 0.57&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;&amp;lt;0.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Platelets (× 10&lt;sup&gt;3&lt;/sup&gt;/μL)&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;417.45 ± 58.16&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;421.87 ± 52.8&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;419.75 ± 60.32&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;0.297&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Monocytes (× 10&lt;sup&gt;3&lt;/sup&gt;/μL)&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;0.6 ± 0.25&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;1.2 ± 0.52&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;1.19 ± 0.65&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;&amp;lt;0.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Serum C-reactive protein (mg/L)&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;2.14 ± 1.56&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;7.8 ± 5.9&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;8.2 ± 6.8&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;&amp;lt;0.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Procalcitonin (ng/mL)&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;0.04 ± 0.02&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;0.18 ± 0.09&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;0.23 ± 0.11&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;&amp;lt;0.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;&lt;sc&gt;d&lt;/sc&gt;-Dimer (quantitative)&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;167.81 ± 99.54&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;415.68 ± 164.3&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;521.67 ± 178.95&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;&amp;lt;0.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Fibrinogen (mg/dL)&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;321.54 ± 102.87&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;408.27 ± 97.64&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;423.38 ± 115.78&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;0.014&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>15888</offset><text>Table 3	 	</text></passage><passage><infon key="file">tbl0003.xml</infon><infon key="id">tbl0003</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;th valign=&quot;top&quot;&gt;Laboratory test&lt;/th&gt;&lt;th valign=&quot;top&quot;&gt;Asymptomatic&lt;/th&gt;&lt;th valign=&quot;top&quot;&gt;Neurologic&lt;/th&gt;&lt;th valign=&quot;top&quot;&gt;Nonneurologic&lt;/th&gt;&lt;th valign=&quot;top&quot;&gt;&lt;italic&gt;p&lt;/italic&gt; Value&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Neutrophils (× 10&lt;sup&gt;3&lt;/sup&gt;/μL)&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;6.22 ± 2.15&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;8.19 ± 3.74&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;10.36 ± 4.98&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;&amp;lt;0.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Lymphocytes (× 10&lt;sup&gt;3&lt;/sup&gt;/μL)&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;2.17 ± 0.92&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;1.06 ± 2.56&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;0.68 ± 0.57&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;&amp;lt;0.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Platelets (× 10&lt;sup&gt;3&lt;/sup&gt;/μL)&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;417.45 ± 58.16&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;421.87 ± 52.8&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;419.75 ± 60.32&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;0.297&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Monocytes (× 10&lt;sup&gt;3&lt;/sup&gt;/μL)&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;0.6 ± 0.25&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;1.2 ± 0.52&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;1.19 ± 0.65&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;&amp;lt;0.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Serum C-reactive protein (mg/L)&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;2.14 ± 1.56&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;7.8 ± 5.9&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;8.2 ± 6.8&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;&amp;lt;0.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Procalcitonin (ng/mL)&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;0.04 ± 0.02&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;0.18 ± 0.09&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;0.23 ± 0.11&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;&amp;lt;0.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;&lt;sc&gt;d&lt;/sc&gt;-Dimer (quantitative)&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;167.81 ± 99.54&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;415.68 ± 164.3&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;521.67 ± 178.95&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;&amp;lt;0.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Fibrinogen (mg/dL)&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;321.54 ± 102.87&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;408.27 ± 97.64&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;423.38 ± 115.78&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;0.014&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>15899</offset><text>Laboratory test	Asymptomatic	Neurologic	Nonneurologic	p Value	 	Neutrophils (× 103/μL)	6.22 ± 2.15	8.19 ± 3.74	10.36 ± 4.98	&lt;0.001	 	Lymphocytes (× 103/μL)	2.17 ± 0.92	1.06 ± 2.56	0.68 ± 0.57	&lt;0.001	 	Platelets (× 103/μL)	417.45 ± 58.16	421.87 ± 52.8	419.75 ± 60.32	0.297	 	Monocytes (× 103/μL)	0.6 ± 0.25	1.2 ± 0.52	1.19 ± 0.65	&lt;0.001	 	Serum C-reactive protein (mg/L)	2.14 ± 1.56	7.8 ± 5.9	8.2 ± 6.8	&lt;0.001	 	Procalcitonin (ng/mL)	0.04 ± 0.02	0.18 ± 0.09	0.23 ± 0.11	&lt;0.001	 	d-Dimer (quantitative)	167.81 ± 99.54	415.68 ± 164.3	521.67 ± 178.95	&lt;0.001	 	Fibrinogen (mg/dL)	321.54 ± 102.87	408.27 ± 97.64	423.38 ± 115.78	0.014	 	</text></passage><passage><infon key="file">tbl0003.xml</infon><infon key="id">tbl0003</infon><infon key="section_type">TABLE</infon><infon key="type">table_footnote</infon><offset>16562</offset><text>Note: Significant p values are shown in boldface.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>16612</offset><text>The results of the systemic examination are shown in Table 1. Thirty-two of the patients with COVID-19 were asymptomatic or paucisymptomatic at the time of admission. Of the remaining patients in the COVID-19 group, 38 had predominantly neurological symptoms, and 59 had predominantly nonneurological symptoms (respiratory in 29, cardiovascular in 17, and gastrointestinal in 13 patients) at the time of admission. Laboratory findings of the study participants with COVID-19 at first visit are presented in Table 3 .</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>17129</offset><text>Optical coherence tomography and optical coherence tomography angiographyscan measurement results</text></passage><passage><infon key="file">tbl0004.xml</infon><infon key="id">tbl0004</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>17227</offset><text>Optical coherence tomography measurements of the study groups</text></passage><passage><infon key="file">tbl0004.xml</infon><infon key="id">tbl0004</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;th valign=&quot;top&quot;&gt;Measurement&lt;/th&gt;&lt;th valign=&quot;top&quot;&gt;Neurologic COVID-19&lt;/th&gt;&lt;th valign=&quot;top&quot;&gt;Nonneurologic COVID-19&lt;/th&gt;&lt;th valign=&quot;top&quot;&gt;Asymptomatic COVID-19&lt;/th&gt;&lt;th valign=&quot;top&quot;&gt;Control&lt;/th&gt;&lt;th valign=&quot;top&quot;&gt;&lt;italic&gt;p&lt;/italic&gt; Value&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;RNFLT (µm), mean&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;104.18 ± 12.48&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;112.85 ± 14.27&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;112.48 ± 14.58&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;113.72 ± 13.42&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;&amp;lt;0.001&lt;xref rid=&quot;tb4fn1&quot; ref-type=&quot;table-fn&quot;&gt;*&lt;/xref&gt;/0.789&lt;xref rid=&quot;tb4fn2&quot; ref-type=&quot;table-fn&quot;&gt;†&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;RNFLT (µm), superior&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;125.78 ± 17.52&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;133.27 ± 16.44&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;134.64 ± 18.54&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;135.38 ± 17.79&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;0.001/0.352&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;RNFLT (µm), nasal&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;72.8 ± 10.1&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;78.2 ± 7.54&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;79.13 ± 8.15&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;79.27 ± 7.98&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;&amp;lt;0.001/0.458&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;RNFLT (µm), inferior&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;136.7 ± 19.45&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;145.87 ± 30.84&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;144.54 ± 32.46&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;145.29 ± 33.55&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;0.002/0.528&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;RNFLT (µm), temporal&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;72.04 ± 13.16&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;75.23 ± 11.45&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;76.83 ± 12.88&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;76.14 ± 12.74&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;0.004/0.744&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;MT (µm), outer ring superior&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;339.54 ± 17.82&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;335.4 ± 19.21&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;336.62 ± 19.81&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;338.64 ± 19.82&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;0.141/0.214&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;MT (µm), outer ring inferior&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;343.19 ± 18.59&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;346.78 ± 17.89&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;344.22 ± 16.79&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;343.25 ± 16.87&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;0.605/0.389&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;MT (µm), outer ring nasal&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;324.76 ± 18.28&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;326.24 ± 18.54&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;325.88 ± 19.23&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;326.76 ± 18.95&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;0.334/0.457&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;MT (µm), outer ring temporal&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;328.44 ± 16.12&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;328.88 ± 19.67&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;325.78 ± 18.23&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;328.44 ± 17.99&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;0.298/0.197&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;MT (µm), inner ring superior&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;352.36 ± 17.26&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;350.26 ± 18.43&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;352.16 ± 16.94&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;349.76 ± 17.83&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;0.117/0.274&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;MT (µm), inner ring inferior&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;343.82 ± 16.55&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;345.82 ± 16.77&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;346.74 ± 14.28&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;342.82 ± 15.37&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;0.159/0.091&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;MT (µm), inner ring nasal&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;344.74 ± 17.29&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;342.88 ± 16.28&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;341.48 ± 15.55&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;342.64 ± 17.16&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;0.798/0.925&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;MT (µm), inner ring temporal&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;328.29 ± 14.57&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;327.48 ± 15.72&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;329.4 ± 14.84&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;328.49 ± 15.58&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;0.682/0.547&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;CFST (1 mm)&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;256.92 ± 18.75&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;257.6 ± 14.66&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;259.04 ± 12.4&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;256.91 ± 14.85&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;0.125/0.243&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;GCCT (µm), upper quadrant&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;95.86 ± 9.11&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;111.24 ± 8.75&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;110.4 ± 7.2&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;108.96 ± 8.1&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;&amp;lt;0.001/0.324&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;GCCT (µm), lower quadrant&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;98.77 ± 6.44&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;111.21 ± 7.13&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;109.9 ± 6.5&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;108.51 ± 7.2&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;&amp;lt;0.001/0.278&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Subfoveal choroidal thickness (µm)&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;276.9 ± 54.28&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;278.11 ± 47.34&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;279.54 ± 52.5&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;277.98 ± 54.1&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;0.317/0.385&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>17289</offset><text>Table 4	 	</text></passage><passage><infon key="file">tbl0004.xml</infon><infon key="id">tbl0004</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;th valign=&quot;top&quot;&gt;Measurement&lt;/th&gt;&lt;th valign=&quot;top&quot;&gt;Neurologic COVID-19&lt;/th&gt;&lt;th valign=&quot;top&quot;&gt;Nonneurologic COVID-19&lt;/th&gt;&lt;th valign=&quot;top&quot;&gt;Asymptomatic COVID-19&lt;/th&gt;&lt;th valign=&quot;top&quot;&gt;Control&lt;/th&gt;&lt;th valign=&quot;top&quot;&gt;&lt;italic&gt;p&lt;/italic&gt; Value&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;RNFLT (µm), mean&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;104.18 ± 12.48&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;112.85 ± 14.27&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;112.48 ± 14.58&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;113.72 ± 13.42&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;&amp;lt;0.001&lt;xref rid=&quot;tb4fn1&quot; ref-type=&quot;table-fn&quot;&gt;*&lt;/xref&gt;/0.789&lt;xref rid=&quot;tb4fn2&quot; ref-type=&quot;table-fn&quot;&gt;†&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;RNFLT (µm), superior&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;125.78 ± 17.52&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;133.27 ± 16.44&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;134.64 ± 18.54&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;135.38 ± 17.79&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;0.001/0.352&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;RNFLT (µm), nasal&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;72.8 ± 10.1&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;78.2 ± 7.54&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;79.13 ± 8.15&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;79.27 ± 7.98&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;&amp;lt;0.001/0.458&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;RNFLT (µm), inferior&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;136.7 ± 19.45&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;145.87 ± 30.84&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;144.54 ± 32.46&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;145.29 ± 33.55&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;0.002/0.528&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;RNFLT (µm), temporal&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;72.04 ± 13.16&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;75.23 ± 11.45&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;76.83 ± 12.88&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;76.14 ± 12.74&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;0.004/0.744&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;MT (µm), outer ring superior&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;339.54 ± 17.82&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;335.4 ± 19.21&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;336.62 ± 19.81&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;338.64 ± 19.82&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;0.141/0.214&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;MT (µm), outer ring inferior&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;343.19 ± 18.59&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;346.78 ± 17.89&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;344.22 ± 16.79&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;343.25 ± 16.87&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;0.605/0.389&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;MT (µm), outer ring nasal&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;324.76 ± 18.28&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;326.24 ± 18.54&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;325.88 ± 19.23&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;326.76 ± 18.95&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;0.334/0.457&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;MT (µm), outer ring temporal&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;328.44 ± 16.12&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;328.88 ± 19.67&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;325.78 ± 18.23&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;328.44 ± 17.99&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;0.298/0.197&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;MT (µm), inner ring superior&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;352.36 ± 17.26&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;350.26 ± 18.43&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;352.16 ± 16.94&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;349.76 ± 17.83&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;0.117/0.274&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;MT (µm), inner ring inferior&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;343.82 ± 16.55&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;345.82 ± 16.77&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;346.74 ± 14.28&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;342.82 ± 15.37&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;0.159/0.091&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;MT (µm), inner ring nasal&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;344.74 ± 17.29&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;342.88 ± 16.28&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;341.48 ± 15.55&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;342.64 ± 17.16&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;0.798/0.925&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;MT (µm), inner ring temporal&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;328.29 ± 14.57&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;327.48 ± 15.72&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;329.4 ± 14.84&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;328.49 ± 15.58&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;0.682/0.547&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;CFST (1 mm)&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;256.92 ± 18.75&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;257.6 ± 14.66&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;259.04 ± 12.4&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;256.91 ± 14.85&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;0.125/0.243&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;GCCT (µm), upper quadrant&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;95.86 ± 9.11&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;111.24 ± 8.75&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;110.4 ± 7.2&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;108.96 ± 8.1&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;&amp;lt;0.001/0.324&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;GCCT (µm), lower quadrant&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;98.77 ± 6.44&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;111.21 ± 7.13&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;109.9 ± 6.5&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;108.51 ± 7.2&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;&amp;lt;0.001/0.278&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Subfoveal choroidal thickness (µm)&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;276.9 ± 54.28&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;278.11 ± 47.34&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;279.54 ± 52.5&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;277.98 ± 54.1&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;0.317/0.385&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>17300</offset><text>Measurement	Neurologic COVID-19	Nonneurologic COVID-19	Asymptomatic COVID-19	Control	p Value	 	RNFLT (µm), mean	104.18 ± 12.48	112.85 ± 14.27	112.48 ± 14.58	113.72 ± 13.42	&lt;0.001*/0.789†	 	RNFLT (µm), superior	125.78 ± 17.52	133.27 ± 16.44	134.64 ± 18.54	135.38 ± 17.79	0.001/0.352	 	RNFLT (µm), nasal	72.8 ± 10.1	78.2 ± 7.54	79.13 ± 8.15	79.27 ± 7.98	&lt;0.001/0.458	 	RNFLT (µm), inferior	136.7 ± 19.45	145.87 ± 30.84	144.54 ± 32.46	145.29 ± 33.55	0.002/0.528	 	RNFLT (µm), temporal	72.04 ± 13.16	75.23 ± 11.45	76.83 ± 12.88	76.14 ± 12.74	0.004/0.744	 	MT (µm), outer ring superior	339.54 ± 17.82	335.4 ± 19.21	336.62 ± 19.81	338.64 ± 19.82	0.141/0.214	 	MT (µm), outer ring inferior	343.19 ± 18.59	346.78 ± 17.89	344.22 ± 16.79	343.25 ± 16.87	0.605/0.389	 	MT (µm), outer ring nasal	324.76 ± 18.28	326.24 ± 18.54	325.88 ± 19.23	326.76 ± 18.95	0.334/0.457	 	MT (µm), outer ring temporal	328.44 ± 16.12	328.88 ± 19.67	325.78 ± 18.23	328.44 ± 17.99	0.298/0.197	 	MT (µm), inner ring superior	352.36 ± 17.26	350.26 ± 18.43	352.16 ± 16.94	349.76 ± 17.83	0.117/0.274	 	MT (µm), inner ring inferior	343.82 ± 16.55	345.82 ± 16.77	346.74 ± 14.28	342.82 ± 15.37	0.159/0.091	 	MT (µm), inner ring nasal	344.74 ± 17.29	342.88 ± 16.28	341.48 ± 15.55	342.64 ± 17.16	0.798/0.925	 	MT (µm), inner ring temporal	328.29 ± 14.57	327.48 ± 15.72	329.4 ± 14.84	328.49 ± 15.58	0.682/0.547	 	CFST (1 mm)	256.92 ± 18.75	257.6 ± 14.66	259.04 ± 12.4	256.91 ± 14.85	0.125/0.243	 	GCCT (µm), upper quadrant	95.86 ± 9.11	111.24 ± 8.75	110.4 ± 7.2	108.96 ± 8.1	&lt;0.001/0.324	 	GCCT (µm), lower quadrant	98.77 ± 6.44	111.21 ± 7.13	109.9 ± 6.5	108.51 ± 7.2	&lt;0.001/0.278	 	Subfoveal choroidal thickness (µm)	276.9 ± 54.28	278.11 ± 47.34	279.54 ± 52.5	277.98 ± 54.1	0.317/0.385	 	</text></passage><passage><infon key="file">tbl0004.xml</infon><infon key="id">tbl0004</infon><infon key="section_type">TABLE</infon><infon key="type">table_footnote</infon><offset>19177</offset><text>RNFLT, retinal nerve fibre layer thickness; MT, macular thickness; CFST, central foveal subfield thickness; GCCT, ganglion cell complex thickness</text></passage><passage><infon key="file">tbl0004.xml</infon><infon key="id">tbl0004</infon><infon key="section_type">TABLE</infon><infon key="type">table_footnote</infon><offset>19323</offset><text>Note: The significant p values are shown in boldface.</text></passage><passage><infon key="file">tbl0004.xml</infon><infon key="id">tbl0004</infon><infon key="section_type">TABLE</infon><infon key="type">table_footnote</infon><offset>19377</offset><text>Difference compared with all remaining groups (ANOVA test).</text></passage><passage><infon key="file">tbl0004.xml</infon><infon key="id">tbl0004</infon><infon key="section_type">TABLE</infon><infon key="type">table_footnote</infon><offset>19437</offset><text>Difference compared with 3 (nonneurological, asymptomatic, and control) groups (ANOVA test).</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>19530</offset><text>The results of the OCT measurements are shown in Table 4 . In all quadrants, the RNFL and GCC were thinner in patients with neurologic COVID-19 symptoms (p &lt; 0.05). None of the measurements of the ETDRS regions significantly differed between the COVID-19 and control groups (p &gt; 0.05).</text></passage><passage><infon key="file">tbl0005.xml</infon><infon key="id">tbl0005</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>19816</offset><text>Measurements of the FAZ area, perimeter and CI, and the vessel densities of SCP, DCP, and RPCP in the study groups</text></passage><passage><infon key="file">tbl0005.xml</infon><infon key="id">tbl0005</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;th valign=&quot;top&quot;&gt;Area&lt;/th&gt;&lt;th valign=&quot;top&quot;&gt;Neurologic COVID-19&lt;/th&gt;&lt;th valign=&quot;top&quot;&gt;Nonneurologic COVID-19&lt;/th&gt;&lt;th valign=&quot;top&quot;&gt;Asymptomatic COVID-19&lt;/th&gt;&lt;th valign=&quot;top&quot;&gt;Control&lt;/th&gt;&lt;th valign=&quot;top&quot;&gt;&lt;italic&gt;P&lt;/italic&gt; (*/¥/ɸ)&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;FAZ area (mm&lt;sup&gt;2&lt;/sup&gt;)&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;0.38 ± 0.21&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;0.37 ± 0.12&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;0.32 ± 0.11&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;0.31 ± 0.15&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;&amp;lt;0.001&lt;xref rid=&quot;tb5fn1&quot; ref-type=&quot;table-fn&quot;&gt;*&lt;/xref&gt;/0.021&lt;xref rid=&quot;tb5fn2&quot; ref-type=&quot;table-fn&quot;&gt;†&lt;/xref&gt;/&amp;lt;0.001&lt;xref rid=&quot;tb5fn3&quot; ref-type=&quot;table-fn&quot;&gt;‡&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;FAZ perimeter (mm)&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;2.99 ± 0.58&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;2.97 ± 0.62&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;2.88 ± 0.54&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;2.9 ± 0.6&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;&amp;lt;0.001/0.001/&amp;lt;0.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;FAZ CI&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;0.37 ± 0.17&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;0.38 ± 0.16&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;0.49 ± 0.2&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;0.52 ± 0.15&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;&amp;lt;0.001/&amp;lt;0.001/&amp;lt;0.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;SCP, global VD (%)&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;38.22 ± 3.75&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;39.1 ± 3.24&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;41.9 ± 2.82&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;42.9 ± 2.3&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;0.001/&amp;lt;0.001/0.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;SCP, inner circle VD (%)&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;34.33 ± 4.11&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;35.24 ± 4.84&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;38.98 ± 4.78&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;39.6 ± 4.2&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;0.001/&amp;lt;0.001/&amp;lt;0.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;SCP, outer circle VD (%)&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;47.85 ± 5.19&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;49.23 ± 5.82&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;51.79 ± 5.9&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;52.01 ± 5.25&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;0.001/0.001/0.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;DCP, global VD (%)&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;34.56 ± 4.75&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;35.22 ± 4.73&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;38.49 ± 4.24&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;38.6 ± 3.98&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;&amp;lt;0.001/&amp;lt;0.001/&amp;lt;0.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;DCP, inner circle VD (%)&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;27.74 ± 4.89&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;28.25 ± 4.92&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;33.82 ± 4.84&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;33.9 ± 5.18&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;&amp;lt;0.001/&amp;lt;0.001/&amp;lt;0.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;DCP, outer circle VD (%)&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;46.8 ± 4.71&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;47.5 ± 4.8&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;53.2 ± 3.52&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;53.75 ± 3.79&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;&amp;lt;0.001/0.001/&amp;lt;0.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;RPCP, global VD (%)&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;50.78 ± 6.12&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;51.39 ± 5.82&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;56.98 ± 5.27&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;57.4 ± 5.19&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;0.001/0.002/.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;RPCP, superior half VD (%)&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;51.68 ± 5.88&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;52.54 ± 4.82&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;57.32 ± 4.85&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;56.98 ± 4.78&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;0.001/0.001/&amp;lt;0.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;RPCP, inferior half VD (%)&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;50.19 ± 5.23&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;52.87 ± 4.35&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;56.83 ± 4.36&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;57.21 ± 4.15&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;&amp;lt;0.001/0.001/&amp;lt;0.001&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>19931</offset><text>Table 5	 	</text></passage><passage><infon key="file">tbl0005.xml</infon><infon key="id">tbl0005</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;th valign=&quot;top&quot;&gt;Area&lt;/th&gt;&lt;th valign=&quot;top&quot;&gt;Neurologic COVID-19&lt;/th&gt;&lt;th valign=&quot;top&quot;&gt;Nonneurologic COVID-19&lt;/th&gt;&lt;th valign=&quot;top&quot;&gt;Asymptomatic COVID-19&lt;/th&gt;&lt;th valign=&quot;top&quot;&gt;Control&lt;/th&gt;&lt;th valign=&quot;top&quot;&gt;&lt;italic&gt;P&lt;/italic&gt; (*/¥/ɸ)&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;FAZ area (mm&lt;sup&gt;2&lt;/sup&gt;)&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;0.38 ± 0.21&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;0.37 ± 0.12&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;0.32 ± 0.11&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;0.31 ± 0.15&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;&amp;lt;0.001&lt;xref rid=&quot;tb5fn1&quot; ref-type=&quot;table-fn&quot;&gt;*&lt;/xref&gt;/0.021&lt;xref rid=&quot;tb5fn2&quot; ref-type=&quot;table-fn&quot;&gt;†&lt;/xref&gt;/&amp;lt;0.001&lt;xref rid=&quot;tb5fn3&quot; ref-type=&quot;table-fn&quot;&gt;‡&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;FAZ perimeter (mm)&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;2.99 ± 0.58&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;2.97 ± 0.62&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;2.88 ± 0.54&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;2.9 ± 0.6&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;&amp;lt;0.001/0.001/&amp;lt;0.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;FAZ CI&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;0.37 ± 0.17&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;0.38 ± 0.16&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;0.49 ± 0.2&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;0.52 ± 0.15&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;&amp;lt;0.001/&amp;lt;0.001/&amp;lt;0.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;SCP, global VD (%)&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;38.22 ± 3.75&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;39.1 ± 3.24&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;41.9 ± 2.82&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;42.9 ± 2.3&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;0.001/&amp;lt;0.001/0.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;SCP, inner circle VD (%)&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;34.33 ± 4.11&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;35.24 ± 4.84&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;38.98 ± 4.78&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;39.6 ± 4.2&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;0.001/&amp;lt;0.001/&amp;lt;0.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;SCP, outer circle VD (%)&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;47.85 ± 5.19&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;49.23 ± 5.82&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;51.79 ± 5.9&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;52.01 ± 5.25&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;0.001/0.001/0.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;DCP, global VD (%)&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;34.56 ± 4.75&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;35.22 ± 4.73&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;38.49 ± 4.24&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;38.6 ± 3.98&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;&amp;lt;0.001/&amp;lt;0.001/&amp;lt;0.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;DCP, inner circle VD (%)&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;27.74 ± 4.89&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;28.25 ± 4.92&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;33.82 ± 4.84&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;33.9 ± 5.18&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;&amp;lt;0.001/&amp;lt;0.001/&amp;lt;0.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;DCP, outer circle VD (%)&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;46.8 ± 4.71&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;47.5 ± 4.8&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;53.2 ± 3.52&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;53.75 ± 3.79&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;&amp;lt;0.001/0.001/&amp;lt;0.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;RPCP, global VD (%)&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;50.78 ± 6.12&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;51.39 ± 5.82&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;56.98 ± 5.27&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;57.4 ± 5.19&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;0.001/0.002/.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;RPCP, superior half VD (%)&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;51.68 ± 5.88&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;52.54 ± 4.82&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;57.32 ± 4.85&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;56.98 ± 4.78&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;0.001/0.001/&amp;lt;0.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;RPCP, inferior half VD (%)&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;50.19 ± 5.23&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;52.87 ± 4.35&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;56.83 ± 4.36&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;57.21 ± 4.15&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;&amp;lt;0.001/0.001/&amp;lt;0.001&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>19942</offset><text>Area	Neurologic COVID-19	Nonneurologic COVID-19	Asymptomatic COVID-19	Control	P (*/¥/ɸ)	 	FAZ area (mm2)	0.38 ± 0.21	0.37 ± 0.12	0.32 ± 0.11	0.31 ± 0.15	&lt;0.001*/0.021†/&lt;0.001‡	 	FAZ perimeter (mm)	2.99 ± 0.58	2.97 ± 0.62	2.88 ± 0.54	2.9 ± 0.6	&lt;0.001/0.001/&lt;0.001	 	FAZ CI	0.37 ± 0.17	0.38 ± 0.16	0.49 ± 0.2	0.52 ± 0.15	&lt;0.001/&lt;0.001/&lt;0.001	 	SCP, global VD (%)	38.22 ± 3.75	39.1 ± 3.24	41.9 ± 2.82	42.9 ± 2.3	0.001/&lt;0.001/0.001	 	SCP, inner circle VD (%)	34.33 ± 4.11	35.24 ± 4.84	38.98 ± 4.78	39.6 ± 4.2	0.001/&lt;0.001/&lt;0.001	 	SCP, outer circle VD (%)	47.85 ± 5.19	49.23 ± 5.82	51.79 ± 5.9	52.01 ± 5.25	0.001/0.001/0.001	 	DCP, global VD (%)	34.56 ± 4.75	35.22 ± 4.73	38.49 ± 4.24	38.6 ± 3.98	&lt;0.001/&lt;0.001/&lt;0.001	 	DCP, inner circle VD (%)	27.74 ± 4.89	28.25 ± 4.92	33.82 ± 4.84	33.9 ± 5.18	&lt;0.001/&lt;0.001/&lt;0.001	 	DCP, outer circle VD (%)	46.8 ± 4.71	47.5 ± 4.8	53.2 ± 3.52	53.75 ± 3.79	&lt;0.001/0.001/&lt;0.001	 	RPCP, global VD (%)	50.78 ± 6.12	51.39 ± 5.82	56.98 ± 5.27	57.4 ± 5.19	0.001/0.002/.001	 	RPCP, superior half VD (%)	51.68 ± 5.88	52.54 ± 4.82	57.32 ± 4.85	56.98 ± 4.78	0.001/0.001/&lt;0.001	 	RPCP, inferior half VD (%)	50.19 ± 5.23	52.87 ± 4.35	56.83 ± 4.36	57.21 ± 4.15	&lt;0.001/0.001/&lt;0.001	 	</text></passage><passage><infon key="file">tbl0005.xml</infon><infon key="id">tbl0005</infon><infon key="section_type">TABLE</infon><infon key="type">table_footnote</infon><offset>21198</offset><text>FAZ = foveal avascular zone; CI = circularity index; SCP = superficial capillary plexus; VD = vessel density; DCP = deep capillary plexus; RPCP = retinal peripapillary capillary plexus</text></passage><passage><infon key="file">tbl0005.xml</infon><infon key="id">tbl0005</infon><infon key="section_type">TABLE</infon><infon key="type">table_footnote</infon><offset>21407</offset><text>Note: Significant p values are shown in boldface.</text></passage><passage><infon key="file">tbl0005.xml</infon><infon key="id">tbl0005</infon><infon key="section_type">TABLE</infon><infon key="type">table_footnote</infon><offset>21457</offset><text>Difference compared with all the remaining groups (ANOVA test).</text></passage><passage><infon key="file">tbl0005.xml</infon><infon key="id">tbl0005</infon><infon key="section_type">TABLE</infon><infon key="type">table_footnote</infon><offset>21521</offset><text>Difference compared with 3 (nonneurologicl, asymptomatic, and control) groups (ANOVA test).</text></passage><passage><infon key="file">tbl0005.xml</infon><infon key="id">tbl0005</infon><infon key="section_type">TABLE</infon><infon key="type">table_footnote</infon><offset>21613</offset><text>Difference compared with symptomatic (neurologic and nonneurologic) groups and nonsymptomatic (asymptomatic and control) groups (t test).</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>21751</offset><text>The mean and SD values of the FAZ area, perimeter and CI, and vessel densities of the SCP, DCP, and RPCP are shown in Table 5 . The FAZ area, perimeter, and CI and the vessel densities (%) of the global, inner, and outer circles of SCP and DCP and global, superior, and inferior parts of the RPCP measurements were found to significantly differ between the symptomatic COVID-19 group and the asymptomatic COVID-19 and control groups (p &lt; 0.05).</text></passage><passage><infon key="file">tbl0006.xml</infon><infon key="id">tbl0006</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>22196</offset><text>Multiple linear regression model between the RNFL and GCC and OCTA parameters in the symptomatic COVID-19 group</text></passage><passage><infon key="file">tbl0006.xml</infon><infon key="id">tbl0006</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;th valign=&quot;top&quot;&gt;Factor&lt;/th&gt;&lt;th valign=&quot;top&quot;&gt;&lt;italic&gt;r&lt;/italic&gt; Value&lt;/th&gt;&lt;th valign=&quot;top&quot;&gt;ANOVA &lt;italic&gt;p&lt;/italic&gt; value&lt;/th&gt;&lt;th valign=&quot;top&quot;&gt;&lt;italic&gt;β&lt;/italic&gt; value&lt;/th&gt;&lt;th valign=&quot;top&quot;&gt;&lt;italic&gt;p&lt;/italic&gt; value&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;RNFL average&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.894&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.001&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;—&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;—&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;FAZ perimeter (mm)&lt;/td&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;2.584&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.003&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;FAZ CI&lt;/td&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;–1.911&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;SCP, global VD (%)&lt;/td&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;0.618&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.124&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;SCP, inner circle VD (%)&lt;/td&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;0.297&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.387&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;SCP, outer circle VD (%)&lt;/td&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;0.465&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.215&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;DCP, global VD (%)&lt;/td&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;2.978&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;DCP, inner circle VD (%)&lt;/td&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;–1.984&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;DCP, outer circle VD (%)&lt;/td&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;2.112&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.002&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;RPCP, global VD (%)&lt;/td&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;–1.499&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.015&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;RPCP, superior half VD (%)&lt;/td&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;0.785&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.003&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;RPCP, inferior half VD (%)&lt;/td&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;–3.147&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.005&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;GCC AVERAGE&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.799&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.002&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;—&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;—&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;FAZ perimeter (mm)&lt;/td&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;–1.768&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;FAZ CI&lt;/td&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;3.678&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.002&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;SCP, global VD (%)&lt;/td&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;0.714&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.687&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;SCP, inner circle VD (%)&lt;/td&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;0.692&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.341&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;SCP, outer circle VD (%)&lt;/td&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;0.315&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.246&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;DCP, global VD (%)&lt;/td&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;1.147&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.003&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;DCP, inner circle VD (%)&lt;/td&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;1.548&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.002&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;DCP, outer circle VD (%)&lt;/td&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;2.479&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;RPCP, global VD (%)&lt;/td&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;–1.984&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;RPCP, superior half VD (%)&lt;/td&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;–2.596&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.007&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;RPCP, inferior half VD (%)&lt;/td&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;2.687&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.003&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>22308</offset><text>Table 6	 	</text></passage><passage><infon key="file">tbl0006.xml</infon><infon key="id">tbl0006</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;th valign=&quot;top&quot;&gt;Factor&lt;/th&gt;&lt;th valign=&quot;top&quot;&gt;&lt;italic&gt;r&lt;/italic&gt; Value&lt;/th&gt;&lt;th valign=&quot;top&quot;&gt;ANOVA &lt;italic&gt;p&lt;/italic&gt; value&lt;/th&gt;&lt;th valign=&quot;top&quot;&gt;&lt;italic&gt;β&lt;/italic&gt; value&lt;/th&gt;&lt;th valign=&quot;top&quot;&gt;&lt;italic&gt;p&lt;/italic&gt; value&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;RNFL average&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.894&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.001&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;—&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;—&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;FAZ perimeter (mm)&lt;/td&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;2.584&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.003&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;FAZ CI&lt;/td&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;–1.911&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;SCP, global VD (%)&lt;/td&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;0.618&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.124&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;SCP, inner circle VD (%)&lt;/td&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;0.297&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.387&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;SCP, outer circle VD (%)&lt;/td&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;0.465&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.215&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;DCP, global VD (%)&lt;/td&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;2.978&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;DCP, inner circle VD (%)&lt;/td&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;–1.984&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;DCP, outer circle VD (%)&lt;/td&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;2.112&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.002&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;RPCP, global VD (%)&lt;/td&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;–1.499&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.015&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;RPCP, superior half VD (%)&lt;/td&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;0.785&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.003&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;RPCP, inferior half VD (%)&lt;/td&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;–3.147&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.005&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;GCC AVERAGE&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.799&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.002&lt;/td&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;—&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;—&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;FAZ perimeter (mm)&lt;/td&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;–1.768&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;FAZ CI&lt;/td&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;3.678&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.002&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;SCP, global VD (%)&lt;/td&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;0.714&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.687&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;SCP, inner circle VD (%)&lt;/td&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;0.692&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.341&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;SCP, outer circle VD (%)&lt;/td&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;0.315&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.246&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;DCP, global VD (%)&lt;/td&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;1.147&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.003&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;DCP, inner circle VD (%)&lt;/td&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;1.548&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.002&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;DCP, outer circle VD (%)&lt;/td&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;2.479&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;RPCP, global VD (%)&lt;/td&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;–1.984&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;RPCP, superior half VD (%)&lt;/td&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;–2.596&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.007&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;RPCP, inferior half VD (%)&lt;/td&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td valign=&quot;top&quot;/&gt;&lt;td align=&quot;char&quot; valign=&quot;top&quot;&gt;2.687&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.003&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>22319</offset><text>Factor	r Value	ANOVA p value	β value	p value	 	RNFL average	0.894	0.001	—	—	 	FAZ perimeter (mm)			2.584	0.003	 	FAZ CI			–1.911	0.001	 	SCP, global VD (%)			0.618	0.124	 	SCP, inner circle VD (%)			0.297	0.387	 	SCP, outer circle VD (%)			0.465	0.215	 	DCP, global VD (%)			2.978	0.001	 	DCP, inner circle VD (%)			–1.984	0.001	 	DCP, outer circle VD (%)			2.112	0.002	 	RPCP, global VD (%)			–1.499	0.015	 	RPCP, superior half VD (%)			0.785	0.003	 	RPCP, inferior half VD (%)			–3.147	0.005	 	GCC AVERAGE	0.799	0.002	—	—	 	FAZ perimeter (mm)			–1.768	0.001	 	FAZ CI			3.678	0.002	 	SCP, global VD (%)			0.714	0.687	 	SCP, inner circle VD (%)			0.692	0.341	 	SCP, outer circle VD (%)			0.315	0.246	 	DCP, global VD (%)			1.147	0.003	 	DCP, inner circle VD (%)			1.548	0.002	 	DCP, outer circle VD (%)			2.479	0.001	 	RPCP, global VD (%)			–1.984	0.001	 	RPCP, superior half VD (%)			–2.596	0.007	 	RPCP, inferior half VD (%)			2.687	0.003	 	</text></passage><passage><infon key="file">tbl0006.xml</infon><infon key="id">tbl0006</infon><infon key="section_type">TABLE</infon><infon key="type">table_footnote</infon><offset>23286</offset><text>ANOVA = analysis of variance; RNFL = retinal nerve fibre layer; GCC = ganglion cell complex; VD = vessel density; FAZ = foveal avascular zone; CI = circularity index; SCP = superficial capillary plexus; DCP = deep capillary plexus; RPCP = retinal peripapillary capillary plexus</text></passage><passage><infon key="file">tbl0006.xml</infon><infon key="id">tbl0006</infon><infon key="section_type">TABLE</infon><infon key="type">table_footnote</infon><offset>23600</offset><text>Note: Significant p values are shown in boldface. Multiple linear regression model, statistically significant P &lt; 0.05.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>23720</offset><text>Multiple regression analyses showed in symptomatic COVID-19 patients a significant relationship between reduced average thickness of the RNFL and GCC and impaired OCT-A parameters (r = 0.894 and r = 0.799; p = 0.001 and p = 0.002, respectively), particularly with DCP, RPCP, and FAZ measurements (Table 6 ).</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">title_1</infon><offset>24040</offset><text>Discussion</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>24051</offset><text>In this study, RNFL and GCC measurements were significantly lower in the patients who presented with the neurologic symptoms of COVID-19 disease. In addition, the SCP, DCP, and RPCP measurements of the patients with symptomatic COVID-19 were significantly lower than those of the asymptomatic COVID-19 and control groups. In the participants with symptomatic COVID-19, the FAZ area and perimeter measurements were significantly higher, and the FAZ CI measurements were significantly lower.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>24541</offset><text>COVID-19 disease has been found to cause prothrombotic status in patients, but its long-term outcomes remain unknown. In COVID-19 disease, many organs and systems are involved because of the direct and indirect effects of the SARS-CoV-2 virus. Therefore, theoretically, COVID-19 can be expected to affect all organs in the body that contain vessels. In patients with symptomatic COVID-19, subnormal oxygenation levels are present, and therefore, supplemental oxygen is required for an extended period. This also can account for retinal vessel density decreases in patients with symptomatic COVID-19. However, this study was performed after patients had completely recovered from COVID-19 disease, and therefore, the acute effects of hypoxia or hyperoxia on retinal vessel density in SARS-CoV-2 infection remain uncertain. Different studies have shown that oxygen status has effects on retinal vessel density lasting from a few minutes to a few days. </text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>25492</offset><text>The reduction in vessel densities can be explained by multiple mechanisms due to COVID-19 infection, including thromboinflammatory microangiopathy and angiotensin-converting enzyme 2 (ACE-2) disruption.   SARS-CoV-2-related microvascular damage is assumed to occur due to complement activation. Complement-mediated thrombotic vasculopathy activates platelet and leukocyte recruitment, coagulation, and endothelial cell dysfunction.   Impairment in the local renin-angiotensin system due to endothelial injury causes the high endothelial expression of ACE-2 receptors that are used by SARS-CoV-2 to enter into the cell. Then endothelial damage results in the hypercoagulopathy and microvessel occlusion seen in COVID-19 infection. An important finding that has been reported previously is that the human eye structures, including the ciliary body, choroid, retina, and retinal pigment epithelium, have significant levels of ACE-2 receptors. Thus COVID-19 infection is considered to damage the chorioretinal vasculature.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>26511</offset><text>Cennamo et al. investigated changes in the retinal vessel density in the macular and papillary regions in patients with post-SARS-CoV-2 pneumonia using OCT-A and found a decrease in the vessel density of the retina in those who had recovered from the disease. Zapata et al. showed that patients with moderate and severe SARS-CoV-2 pneumonia had decreased central retinal vessel densities compared with asymptomatic or paucisymptomatic patients or control subjects. Similarly, in this study, the vessel densities of the SCP, DCP, and RPCP were significantly lower in the symptomatic COVID-19 group. Savastano et al. reported a reduction in the RPCP vessel densities of patients 1 month after they had recovered from COVID-19. However, Abrishami et al. found that the SCP and DCP vessel densities were reduced in COVID-19 patients versus normal control subjects and that the FAZ was enlarged. In this study, the vessel densities of the SCP, DCP, and RPCP were reduced in the COVID-19 group according to the OCT-A measurements.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>27536</offset><text>In this study, OCT and OCT-A showed a significant relationship between the RNFL and GCC thicknesses and the DCP and RPCP in symptomatic COVID-19 patients. Yu et al. reported a positive correlation between RPCP density and RNFL thickness in the same healthy human eyes in their study. There was no relationship between OCT parameters and SCP values in symptomatic COVID-19 patients in that study. The vascular structure of the DCP is characterized by a fine capillary network that makes it more vulnerable to thrombotic events than to the greater vascular diameter of the SCP. These previous studies support the multiple regression analyses results of our study.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>28198</offset><text>This study has certain limitations. First, because the patients were not evaluated in the acute period of the infection, we did not have the chance to observe the possible retinal findings of any patient in the active phase of COVID-19. Second, patients with cardiovascular symptoms were not examined as a separate group, and potential retinal vascular effects were not examined. Third, because of the low number of patients requiring intensive care with very severe COVID-19 findings, we were not able to determine whether OCT-A findings are affected more seriously in this subgroup. Fourth, long-term follow-up data were not available because the disease is caused by a novel coronavirus, and more time is needed to perform a long-term evaluation. Lastly, this study analyzed only the macular and peripapillary retinal vessel densities, and fluorescein angiography was not undertaken to investigate the peripheral retina.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>29122</offset><text>In conclusion, retinal microvascular changes were observed with OCT-A following COVID-19 infection in clinically asymptomatic eyes. Vessel density evaluation with OCT-A can be considered a remarkable diagnostics method for retinal neurovascular abnormalities and a biomarker for microvascular abnormalities after a SARS-CoV-2 infection. Further studies are needed to evaluate the relationship between the OCT-A parameters and both the onset and the duration of COVID-19 infection.</text></passage><passage><infon key="section_type">COMP_INT</infon><infon key="type">title_1</infon><offset>29603</offset><text>Footnotes and Disclosure</text></passage><passage><infon key="section_type">COMP_INT</infon><infon key="type">paragraph</infon><offset>29628</offset><text>The authors state that they have no conflicts of interest concerning the publication of this article. This study was not funded, and the authors accept responsibility for the entire contents of this article and approve its submission.</text></passage><passage><infon key="section_type">COMP_INT</infon><infon key="type">paragraph</infon><offset>29863</offset><text>Data availability: The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available because of restrictions, for example, their containing information that could compromise the privacy of research participants.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">title</infon><offset>30150</offset><text>References</text></passage><passage><infon key="fpage">1239</infon><infon key="lpage">1242</infon><infon key="name_0">surname:Wu;given-names:Z</infon><infon key="name_1">surname:McGoogan;given-names:JM.</infon><infon key="pub-id_pmid">32091533</infon><infon key="section_type">REF</infon><infon key="source">JAMA</infon><infon key="type">ref</infon><infon key="volume">323</infon><infon key="year">2020</infon><offset>30161</offset><text>Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72,314 cases from the Chinese Center for Disease Control and Prevention</text></passage><passage><infon key="fpage">1061</infon><infon key="lpage">1069</infon><infon key="name_0">surname:Wang;given-names:D</infon><infon key="name_1">surname:Hu;given-names:B</infon><infon key="name_2">surname:Hu;given-names:C</infon><infon key="pub-id_pmid">32031570</infon><infon key="section_type">REF</infon><infon key="source">JAMA</infon><infon key="type">ref</infon><infon key="volume">323</infon><infon key="year">2020</infon><offset>30361</offset><text>Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China</text></passage><passage><infon key="name_0">surname:Rothan;given-names:HA</infon><infon key="name_1">surname:Byrareddy;given-names:SN.</infon><infon key="section_type">REF</infon><infon key="source">J Autoimmun</infon><infon key="type">ref</infon><infon key="volume">109</infon><infon key="year">2020</infon><offset>30480</offset><text>The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>30557</offset><text>The World Health Organization coronavirus disease 2019 (COVID-19) situation report e61 [Internet]. Available from:https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200321-sitrep-61-covid-19.pdf? sfvrsn¼f201f85c_2 (accessed March 22, 2020).</text></passage><passage><infon key="fpage">69</infon><infon key="name_0">surname:Heneka;given-names:MT</infon><infon key="name_1">surname:Golenbock;given-names:D</infon><infon key="name_2">surname:Latz;given-names:E</infon><infon key="name_3">surname:Morgan;given-names:D</infon><infon key="name_4">surname:Brown;given-names:R.</infon><infon key="pub-id_pmid">32498691</infon><infon key="section_type">REF</infon><infon key="source">Alzheimers Res Ther</infon><infon key="type">ref</infon><infon key="volume">12</infon><infon key="year">2020</infon><offset>30822</offset><text>Immediate and long-term consequences of COVID-19 infections for the development of neurological disease</text></passage><passage><infon key="fpage">14</infon><infon key="lpage">22</infon><infon key="name_0">surname:Whittaker;given-names:A</infon><infon key="name_1">surname:Anson;given-names:M</infon><infon key="name_2">surname:Harky;given-names:A.</infon><infon key="pub-id_pmid">32412088</infon><infon key="section_type">REF</infon><infon key="source">Acta Neurol Scand</infon><infon key="type">ref</infon><infon key="volume">142</infon><infon key="year">2020</infon><offset>30926</offset><text>Neurological manifestations of COVID-19: a systematic review and current update</text></passage><passage><infon key="fpage">1903</infon><infon key="lpage">1914</infon><infon key="name_0">surname:Hendren;given-names:NS</infon><infon key="name_1">surname:Drazner;given-names:MH</infon><infon key="name_2">surname:Bozkurt;given-names:B</infon><infon key="name_3">surname:Cooper;given-names:LT;suffix:Jr.</infon><infon key="pub-id_pmid">32297796</infon><infon key="section_type">REF</infon><infon key="source">Circulation</infon><infon key="type">ref</infon><infon key="volume">141</infon><infon key="year">2020</infon><offset>31006</offset><text>Description and proposed management of the acute COVID-19 cardiovascular syndrome</text></passage><passage><infon key="fpage">721</infon><infon key="issue">5</infon><infon key="lpage">725</infon><infon key="name_0">surname:Casagrande;given-names:M</infon><infon key="name_1">surname:Fitzek;given-names:A</infon><infon key="name_2">surname:Püschel;given-names:K</infon><infon key="pub-id_pmid">32469258</infon><infon key="section_type">REF</infon><infon key="source">Ocul Immunol Inflamm</infon><infon key="type">ref</infon><infon key="volume">28</infon><infon key="year">2020</infon><offset>31088</offset><text>Detection of SARS-CoV-2 in human retinal biopsies of deceased COVID-19 patients</text></passage><passage><infon key="fpage">1610</infon><infon key="name_0">surname:Marinho;given-names:PM</infon><infon key="name_1">surname:Marcos;given-names:AAA</infon><infon key="name_2">surname:Romano;given-names:AC</infon><infon key="name_3">surname:Nascimento;given-names:H</infon><infon key="name_4">surname:Belfort;given-names:R;suffix:Jr.</infon><infon key="pub-id_pmid">32405105</infon><infon key="section_type">REF</infon><infon key="source">Lancet</infon><infon key="type">ref</infon><infon key="volume">395</infon><infon key="year">2020</infon><offset>31168</offset><text>Retinal findings in patients with COVID-19</text></passage><passage><infon key="fpage">557</infon><infon key="lpage">560</infon><infon key="name_0">surname:Liu;given-names:Y</infon><infon key="name_1">surname:Ning;given-names:Z</infon><infon key="name_2">surname:Chen;given-names:Y</infon><infon key="pub-id_pmid">32340022</infon><infon key="section_type">REF</infon><infon key="source">Nature</infon><infon key="type">ref</infon><infon key="volume">582</infon><infon key="year">2020</infon><offset>31211</offset><text>Aerodynamic analysis of SARS-CoV-2 in two Wuhan hospitals</text></passage><passage><infon key="fpage">461</infon><infon key="lpage">468</infon><infon key="name_0">surname:Mucha;given-names:SR</infon><infon key="name_1">surname:Dugar;given-names:S</infon><infon key="name_2">surname:McCrae;given-names:K</infon><infon key="pub-id_pmid">32409435</infon><infon key="section_type">REF</infon><infon key="source">Cleve Clin J Med</infon><infon key="type">ref</infon><infon key="volume">87</infon><infon key="year">2020</infon><offset>31269</offset><text>Coagulopathy in COVID-19</text></passage><passage><infon key="fpage">1421</infon><infon key="lpage">1424</infon><infon key="name_0">surname:Cui;given-names:S</infon><infon key="name_1">surname:Chen;given-names:S</infon><infon key="name_2">surname:Li;given-names:X</infon><infon key="name_3">surname:Liu;given-names:S</infon><infon key="name_4">surname:Wang;given-names:F.</infon><infon key="pub-id_pmid">32271988</infon><infon key="section_type">REF</infon><infon key="source">J Thromb Haemost</infon><infon key="type">ref</infon><infon key="volume">18</infon><infon key="year">2020</infon><offset>31294</offset><text>Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia</text></passage><passage><infon key="fpage">173</infon><infon key="lpage">177</infon><infon key="name_0">surname:Kasinathan;given-names:G</infon><infon key="name_1">surname:Sathar;given-names:J.</infon><infon key="section_type">REF</infon><infon key="source">Ann Med Surg</infon><infon key="type">ref</infon><infon key="volume">56</infon><infon key="year">2020</infon><offset>31383</offset><text>Haematological manifestations, mechanisms of thrombosis and anticoagulation in COVID-19 disease: a review</text></passage><passage><infon key="fpage">e315</infon><infon key="lpage">e319</infon><infon key="name_0">surname:Sousa;given-names:DC</infon><infon key="name_1">surname:Leal;given-names:I</infon><infon key="name_2">surname:Moreira;given-names:S</infon><infon key="name_3">surname:Dionísio;given-names:P</infon><infon key="name_4">surname:Abegão Pinto;given-names:L</infon><infon key="name_5">surname:Marques-Neves;given-names:C</infon><infon key="pub-id_pmid">29160042</infon><infon key="section_type">REF</infon><infon key="source">Acta Ophthalmol</infon><infon key="type">ref</infon><infon key="volume">96</infon><infon key="year">2018</infon><offset>31489</offset><text>Hypoxia challenge test and retinal circulation changes: a study using ocular coherence tomography angiography</text></passage><passage><infon key="fpage">329</infon><infon key="lpage">336</infon><infon key="name_0">surname:Hagag;given-names:AM</infon><infon key="name_1">surname:Pechauer;given-names:AD</infon><infon key="name_2">surname:Liu;given-names:L</infon><infon key="pub-id_pmid">29888339</infon><infon key="section_type">REF</infon><infon key="source">Ophthalmol Retina</infon><infon key="type">ref</infon><infon key="volume">2</infon><infon key="year">2018</infon><offset>31599</offset><text>OCT angiography changes in the 3 parafoveal retinal plexuses in response to hyperoxia</text></passage><passage><infon key="fpage">4464</infon><infon key="name_0">surname:Xu;given-names:H</infon><infon key="name_1">surname:Deng;given-names:G</infon><infon key="name_2">surname:Jiang;given-names:C</infon><infon key="name_3">surname:Kong;given-names:X</infon><infon key="name_4">surname:Yu;given-names:J</infon><infon key="name_5">surname:Sun;given-names:X.</infon><infon key="pub-id_pmid">27750288</infon><infon key="section_type">REF</infon><infon key="source">Invest Ophthalmol Vis Sci</infon><infon key="type">ref</infon><infon key="volume">57</infon><infon key="year">2016</infon><offset>31685</offset><text>Microcirculatory responses to hyperoxia in macular and peripapillary regions</text></passage><passage><infon key="fpage">243</infon><infon key="lpage">247</infon><infon key="name_0">surname:Vinci;given-names:R</infon><infon key="name_1">surname:Pedicino;given-names:D</infon><infon key="name_2">surname:Andreotti;given-names:F</infon><infon key="pub-id_pmid">33181158</infon><infon key="section_type">REF</infon><infon key="source">Int J Cardiol</infon><infon key="type">ref</infon><infon key="volume">326</infon><infon key="year">2021</infon><offset>31762</offset><text>From angiotensin-converting enzyme 2 disruption to thromboinflammatory microvascular disease: a paradigm drawn from COVID-19</text></passage><passage><infon key="fpage">1629</infon><infon key="lpage">1641</infon><infon key="name_0">surname:Gencer;given-names:S</infon><infon key="name_1">surname:Lacy;given-names:M</infon><infon key="name_2">surname:Atzler;given-names:D</infon><infon key="name_3">surname:van der Vorst;given-names:EPC</infon><infon key="name_4">surname:Döring;given-names:Y</infon><infon key="name_5">surname:Weber;given-names:C.</infon><infon key="pub-id_pmid">33124029</infon><infon key="section_type">REF</infon><infon key="source">Thromb Haemost</infon><infon key="type">ref</infon><infon key="volume">120</infon><infon key="year">2020</infon><offset>31887</offset><text>Immunoinflammatory, thrombohaemostatic, and cardiovascular mechanisms in COVID-19</text></passage><passage><infon key="fpage">e38</infon><infon key="name_0">surname:Zhang;given-names:Y</infon><infon key="name_1">surname:Xiao;given-names:M</infon><infon key="name_2">surname:Zhang;given-names:S</infon><infon key="pub-id_pmid">32268022</infon><infon key="section_type">REF</infon><infon key="source">N Engl J Med</infon><infon key="type">ref</infon><infon key="volume">382</infon><infon key="year">2020</infon><offset>31969</offset><text>Coagulopathy and antiphospholipid antibodies in patients with COVID-19</text></passage><passage><infon key="fpage">e227</infon><infon key="lpage">e230</infon><infon key="name_0">surname:Gavriilaki;given-names:E</infon><infon key="name_1">surname:Brodsky;given-names:RA</infon><infon key="pub-id_pmid">32369610</infon><infon key="section_type">REF</infon><infon key="source">Br J Haematol</infon><infon key="type">ref</infon><infon key="volume">189</infon><infon key="year">2020</infon><offset>32040</offset><text>Severe COVID-19 infection and thrombotic microangiopathy: success does not come easily</text></passage><passage><infon key="fpage">757</infon><infon key="lpage">763</infon><infon key="name_0">surname:Bellinvia;given-names:S</infon><infon key="name_1">surname:Edwards;given-names:CJ</infon><infon key="name_2">surname:Schisano;given-names:M</infon><infon key="name_3">surname:Banfi;given-names:P</infon><infon key="name_4">surname:Fallico;given-names:M</infon><infon key="name_5">surname:Murabito;given-names:P.</infon><infon key="pub-id_pmid">32468151</infon><infon key="section_type">REF</infon><infon key="source">Inflamm Res</infon><infon key="type">ref</infon><infon key="volume">69</infon><infon key="year">2020</infon><offset>32127</offset><text>The unleashing of the immune system in COVID-19 and sepsis: the calm before the storm?</text></passage><passage><infon key="fpage">243</infon><infon key="lpage">246</infon><infon key="name_0">surname:Strain;given-names:WD</infon><infon key="name_1">surname:Chaturvedi;given-names:N.</infon><infon key="pub-id_pmid">12584667</infon><infon key="section_type">REF</infon><infon key="source">J Renin Angiotensin Aldosterone Syst</infon><infon key="type">ref</infon><infon key="volume">3</infon><infon key="year">2002</infon><offset>32214</offset><text>The renin-angiotensin-aldosterone system and the eye in diabetes</text></passage><passage><infon key="fpage">182</infon><infon key="lpage">190</infon><infon key="name_0">surname:Cennamo;given-names:G</infon><infon key="name_1">surname:Reibaldi;given-names:M</infon><infon key="name_2">surname:Montorio;given-names:D</infon><infon key="name_3">surname:D'Andrea;given-names:L</infon><infon key="name_4">surname:Fallico;given-names:M</infon><infon key="name_5">surname:Triassi;given-names:M</infon><infon key="pub-id_pmid">33781767</infon><infon key="section_type">REF</infon><infon key="source">Am J Ophthalmol</infon><infon key="type">ref</infon><infon key="volume">227</infon><infon key="year">2021</infon><offset>32279</offset><text>Optical coherence tomography angiography features in post-COVID-19 pneumonia patients: a pilot study</text></passage><passage><infon key="fpage">559</infon><infon key="lpage">563</infon><infon key="name_0">surname:MÁ;given-names:Zapata</infon><infon key="name_1">surname:S;given-names:Banderas García</infon><infon key="name_2">surname:Sánchez-Moltalvá;given-names:A</infon><infon key="pub-id_pmid">33328184</infon><infon key="section_type">REF</infon><infon key="source">Br J Ophthalmol</infon><infon key="type">ref</infon><infon key="volume">106</infon><infon key="year">2020</infon><offset>32380</offset><text>Retinal microvascular abnormalities in patients after COVID-19 depending on disease severity</text></passage><passage><infon key="fpage">2895</infon><infon key="name_0">surname:Savastano;given-names:A</infon><infon key="name_1">surname:Crincoli;given-names:E</infon><infon key="name_2">surname:Savastano;given-names:MC</infon><infon key="section_type">REF</infon><infon key="source">J Clin Med</infon><infon key="type">ref</infon><infon key="volume">9</infon><infon key="year">2020</infon><offset>32473</offset><text>Peripapillary retinal vascular involvement in early post-COVID-19 patients</text></passage><passage><infon key="fpage">24</infon><infon key="lpage">30</infon><infon key="name_0">surname:Abrishami;given-names:M</infon><infon key="name_1">surname:Emamverdian;given-names:Z</infon><infon key="name_2">surname:Shoeibi;given-names:N</infon><infon key="pub-id_pmid">33249111</infon><infon key="section_type">REF</infon><infon key="source">Can J Ophthalmol</infon><infon key="type">ref</infon><infon key="volume">56</infon><infon key="year">2021</infon><offset>32548</offset><text>Optical coherence tomography angiography analysis of the retina in patients recovered from COVID-19: a case-control study</text></passage><passage><infon key="name_0">surname:Yu;given-names:PK</infon><infon key="name_1">surname:Balaratnasingam;given-names:C</infon><infon key="name_2">surname:Xu;given-names:J</infon><infon key="section_type">REF</infon><infon key="source">PLoS One</infon><infon key="type">ref</infon><infon key="volume">10</infon><infon key="year">2015</infon><offset>32670</offset><text>Label-free density measurements of radial peripapillary capillaries in the human retina</text></passage><passage><infon key="fpage">247</infon><infon key="lpage">258</infon><infon key="name_0">surname:Lavia;given-names:C</infon><infon key="name_1">surname:Bonnin;given-names:S</infon><infon key="name_2">surname:Maule;given-names:M</infon><infon key="name_3">surname:Erginay;given-names:A</infon><infon key="name_4">surname:Tadayoni;given-names:R</infon><infon key="name_5">surname:Gaudric;given-names:A.</infon><infon key="pub-id_pmid">30550527</infon><infon key="section_type">REF</infon><infon key="source">Retina</infon><infon key="type">ref</infon><infon key="volume">39</infon><infon key="year">2019</infon><offset>32758</offset><text>Vessel density of superficial, intermediate, and deep capillary plexuses using optical coherence tomography angiography</text></passage></document></collection>
